Screener
Supernus Pharmaceuticals SUPN Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| (unaudited) | ||
| Accounts payable | $10,171 | $2,677 |
| Accrued compensation, benefits, & related accruals | 24,210 | 29,446 |
| Accrued sales & marketing | 16,124 | 16,665 |
| Accrued manufacturing expenses | 20,689 | 25,608 |
| Accrued R&D expenses | 3,774 | 7,299 |
| Operating lease liabilities, current portion(a) | 10,636 | 10,612 |
| Accrued royalties(b) | 1,632 | 2,403 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's accrued expenses?
- Supernus Pharmaceuticals (SUPN) reported accrued expenses of $24.21M in Q1 2026.
- How has Supernus Pharmaceuticals's accrued expenses changed year-over-year?
- Supernus Pharmaceuticals's accrued expenses increased by 37.6% year-over-year, from $17.6M to $24.21M.
- What is the long-term trend for Supernus Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accrued expenses has grown at a 26.5% compound annual growth rate (CAGR), from $9.08M to $29.45M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Supernus Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude